Compare Danaher Corporation (DHR) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs ProShares UltraPro S&P500 — how do they compare? Danaher Corporation trades at $217.43 (market cap $152.87B), while ProShares UltraPro S&P500 trades at $154.92 (market cap $5.55B). The key difference: Danaher Corporation is far larger — about 27.5× ProShares UltraPro S&P500's market cap, and Danaher Corporation pays a 0.74% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and ProShares UltraPro S&P500 for 29 Days on average.
| DHR | UPRO | |
|---|---|---|
Market Cap | $152.87B | $5.55B |
Volume | 5,228,698 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $157.66 |
52-Week Low | $161.91 | $89.29 |
Typical Hold Time | 69 Days | 29 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
UPRO trades at $155.21, down 0.77% for the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces resistance near $156-$160 with support at $151-$147. Recent news highlights S&P 500 valuation concerns and projected earnings growth slowdown from 35% in 2026 to 15% in 2027, creating mixed sentiment around leveraged ETF performance.
Outlook remains cautiously optimistic given the bullish technical setup, though leveraged nature amplifies risks from market volatility and earnings growth deceleration. Key opportunities include potential year-end rally patterns, while risks center on concentrated market exposure and macroeconomic headwinds affecting the underlying index performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
